Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in advanced breast cancer
NCT06966453Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 2, open-label trial of disitamab vedotin in breast cancer, sponsored by Pfizer. Started Jun 2025; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06966453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966453.